These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 13669031)

  • 1. Mel W, a new trypanosomicidal agent derived from mel B.
    FRIEDHEIM EA; DE JONGH RT
    Trans R Soc Trop Med Hyg; 1959 May; 53(3):262-9. PubMed ID: 13669031
    [No Abstract]   [Full Text] [Related]  

  • 2. [New contribution on arsobal (R.P. 3854) therapy of trypanosomiasis; its effectiveness in former trypanosomiasis patients, with meningoencephalitis, resistant to trypanocides customarily used].
    CECCALDI J
    Bull Soc Pathol Exot Filiales; 1953; 46(1):95-121. PubMed ID: 13066959
    [No Abstract]   [Full Text] [Related]  

  • 3. The therapeutic effect on a group of sleeping sickness patients of a single injection of 3854 R.P. (mel B Friedheim-arsobal Spécia).
    PINTO AR
    Am J Trop Med Hyg; 1954 May; 3(3):464-5. PubMed ID: 13158766
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsobal in the treatment of Rhodesian sleeping-sickness.
    SILVA MA; CASEIRO A; CARMO RP; DE BASTO AX
    An Inst Med Trop (Lisb); 1954 Jun; 11(2):261-85. PubMed ID: 13314057
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of advanced trypanosomiasis rhodesiense with mel B.
    TAUBE E; NIXON LC
    Cent Afr J Med; 1958 Apr; 4(4):141-7. PubMed ID: 13547140
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of advanced cases of Rhodesian sleeping sickness by Mel. B. and arsobal.
    APTED FI
    Trans R Soc Trop Med Hyg; 1953 Sep; 47(5):387-98. PubMed ID: 13102579
    [No Abstract]   [Full Text] [Related]  

  • 7. Mel B in the treatment of human trypanosomiasis.
    FRIEDHEIM EA
    Am J Trop Med Hyg; 1949 Mar; 29(2):173-80. PubMed ID: 18116843
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of arsobal in the treatment of sleeping sickness].
    NEUJEAN G
    An Inst Med Trop (Lisb); 1952 Sep; 9(3):757-61. PubMed ID: 13092457
    [No Abstract]   [Full Text] [Related]  

  • 9. Trypanosoma brucei brucei: the response to Melarsoprol in mice with cerebral trypanosomiasis. An immunopathological study.
    Poltera AA; Hochmann A; Lambert PH
    Clin Exp Immunol; 1981 Nov; 46(2):363-74. PubMed ID: 7039886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of the therapy of human African trypanosomiasis].
    Dumas M; Breton JC; Pestre Alexandre M; Girard PL; Giordano C
    Presse Med; 1985 Feb; 14(5):253-6. PubMed ID: 3157106
    [No Abstract]   [Full Text] [Related]  

  • 11. Relative efficacy of melarsen oxide compared with mel Cy (Cymelarsan) when used in combination with difluoromethylornithine in the treatment of trypanosomiasis of the central nervous system.
    Jennings FW
    Trans R Soc Trop Med Hyg; 1992; 86(3):257-8. PubMed ID: 1412647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mel B in the treatment of tryparsamide resistant T. gambiense sleeping sickness: observations on drug resistance in the trypanosomes of the French Cameroun.
    FRIEDHEIM EA
    Am J Trop Med Hyg; 1951 Mar; 31(2):218-35. PubMed ID: 14819516
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Mel B, resistance in Rhodesian sleeping sickness.
    Ogada T
    East Afr Med J; 1974 Jan; 51(1):56-9. PubMed ID: 4839238
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimation of the concentration of melarsoprol (Mel B) and Mel W in biological fluids by bioassay with trypanosomes in vitro.
    HAWKING F
    Trans R Soc Trop Med Hyg; 1962 Sep; 56():354-63. PubMed ID: 13953207
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.
    Koshiuka K; Elstner E; Williamson E; Said JW; Tada Y; Koeffler HP
    Br J Cancer; 2000 Jan; 82(2):452-8. PubMed ID: 10646904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arsenical-induced encephalopathy during the treatment of African trypanosomiasis. Apropos of a case with a favorable outcome].
    Pialoux G; Kernbaum S; Vachon F
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):555-6. PubMed ID: 3197251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arsenical resistance and difluoromethylornithine in the treatment of human African trypanosomiasis].
    Kazyumba GL; Ruppol JF; Tshefu AK; Nkanga N
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):591-4. PubMed ID: 3143492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [African trypanosomiasis, virus disease, Mel B and encephalitis].
    JANSSENS PG; VAN BOGAERT L; MICHIELS A; VAN DE STEEN R
    Ann Soc Belg Med Trop (1920); 1960 Oct; 40():759-69. PubMed ID: 13789507
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of an arsenical compound (RM 110, mel Cy, Cymelarsan) against susceptible and drug-resistant Trypanosoma brucei brucei and T.b. evansi.
    Zweygarth E; Kaminsky R
    Trop Med Parasitol; 1990 Jun; 41(2):208-12. PubMed ID: 2382101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
    Maina N; Maina KJ; Mäser P; Brun R
    Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.